About
Dr Lal Pathlabs Ltd
Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service centers and 10,938 pickup points as of 31 March 2023. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. Apart from these, the catalogue of services includes 481 test panels, 2763 pathology tests and 1947 radiology and cardiology tests.
Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s. Central Clinical Laboratory and M/s. Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt. Ltd.'
Dr. Lal PathLabs Limited was incorporated as a a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi. The business of the Partnership Firm, Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company converted into a Public Limited pursuant to a Special Resolution of the Shareholders of the Company at an EGM held on August 7, 2015. Consequently, name of the Company was changed to Dr. Lal PathLabs Limited' and a fresh Certificate of Incorporation pursuant to the change of name was granted by the RoC on August 19, 2015.
The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited.
The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the Company with the Company with effect from 1 April 2017. The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Hon'ble National Company Law Tribunal (NCLT), on October 23, 2018 and December 11, 2018 respectively. Pursuant thereto, in accordance with the terms of the scheme, Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1, 2017 (being the appointed date) and consequently stands dissolved without winding up.
The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh.
On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.
Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international arena.
During the FY2019, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12, 2018, respectively, as wholly owned subsidiaries of the Company. As on 31 March 2019,the company has 5 domestic and 3 overseas subsidiaries under its roof.
The Board of Directors of your Company in their meeting held on February 3, 2020, approved a Scheme of Amalgamation ('the Scheme') between the Company and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company. The Company is in the process of filing a petition Application before the National Company Law Tribunal, New Delhi for approval of the Scheme of Amalgamation.
During the FY2020, Company's Wholly Owned Subsidiary viz M/s. PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s. APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company. Also Dr. Lal PathLabs Kenya Private Limited was incorporated on August 6, 2019, as a Wholly Owned Subsidiary of the Company in Kenya. The Company has subscribed to equity share capital amounting to KES 10 million (Rs 7.10 million) consisting of 9,880 shares of KES 100.
As on 31 March 2020,the company has 7 domestic and 4 overseas subsidiaries under its roof.
During the year 2019-20, the Company has made a further investment of Rs 599.00 million and Rs 9.00 million in this subsidiary Company Pathlabs Unifiers Private Limited and Dr. Lal Ventures Private Limited respectively through subscription of additional shares.
During the quarter ended 30 June 2020,the company has made a further investment of Rs 15 million in its whollyowned subsidiary Pathlabs Unifiers Private Ltd,through subscription of additional equity shares.
Subsequent to the quarter ended 30 September 2020,pursuant to approval of the Board of Directors of Pathlabs Unifiers Private Ltd(PUPL),a whollyowned subsidiary,PUPL has signed binding term sheets on 06 November 2020,for the acquisition of the business of Bindish Diagnostic Laboratory LLP,Gujarat,on a going concern basis,for a purchase consideration not exceeding Rs 40 million and equity stake of 40% in ChanRe Diagnostic Services Private Ltd,Bengaluru,for a purchase consideration not exceeding Rs 175 million. Both of these companies are engaged in providing pathological diagnostic services.
During the quarter ended 31 December 2020, the company has made a further investment of Rs 225 million in its whollyowned subsidiary,Pathlabs Unifiers Private Ltd,through subscription of additional equity shares. Also the company made a further investment of Rs 40 million in its whollyowned overseas subsidiary,Dr.Lal Pathlabs Kenya Private Ltd,through subscription of additional equity shares.
During year 2020-21, the Company added 15 labs, 600 collection center and 2200 pick-up points. It had overall 231 clinical labs, 3,705 patient service centres and 9,247 pickup-up points as on March 31, 2021.
The Board of Directors of the Company in their meeting on February 3, 2020, approved a Scheme of Amalgamation between Dr. Lal PathLabs Limited (the Transferee Company) and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company (Transferor Company), which was sanctioned on May 13, 2022 and the appointed date for the Scheme is April 1, 2020.
During the year 2021-22, the Company acquired 100% stake in M/s Suburban Diagnostics (India) Private Limited and consequently, Suburban became a Wholly Owned Subsidiary of the Company, effective November 12, 2021. It introduced 46 labs, 1,026 patient service centers and 1,352 pick-up points.
The Company opened its Reference Lab at Vidyavihar, in Mumbai in Jan' 23. Dr. Lal PathLabs expanded its National Reference Lab in Rohini, Delhi, by acquiring a second electron microscope, an upgraded lab information system and advanced tools such as artificial intelligence and data mining.
During FY 2023, the Company operated a network of 277 clinical labs, including the prestigious National Reference Lab in Delhi and the Regional Reference Lab in Kolkata, Bangalore and Mumbai. Additionally, with 5,102 Patient Service Centres (PSCs) and 10,938 Pick-up Points (PUPs), the Company has established a nationwide presence. APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of Company (APL/ Transferor Company), was amalgamated with Dr. Lal PathLabs Limited (the Company/ Transferee Company) effective on March 27, 2023. The Company launched 134 tests in FY' 23 to expand the Super Specialty Portfolio.
Dr Lal Pathlabs Ltd
Chairman Speech
Dear Shareholders,
It gives me immense pleasure to share with you again at the conclusion of a productive
year. Before I begin I hope all of you are in great health and high spirits.
At Dr. Lal PathLabs, we have been very tactfully increasing our presence across the
country, which is otherwise fragmented and dominated by unorganised players. We are the
leader amongst three lakhs odd clinical laboratories in India. This is because of our
unwavering commitment to provide our patients and customers with high-quality diagnostics
at competitive prices, while providing them with a superior testing experience via an
omnichannel approach. This is precisely in accordance with our internal strategy to reach
more consumers in various Indian cities. Today, we have substantially strengthened our
presence in the best-in-class quality of services provided across the entire spectrum of
tests. In addition to establishing an excellent lab network, we have invested heavily in
the brand to leave a lasting impression on consumers. We were the first to recognize that
India requires quality diagnostics that are accessible to the masses everywhere in India.
In line with this, over the years, we have tracked the gradual evolution of modern
medicine in the management of our patients. Since, seventy percent of all medical
decisions are based on laboratory tests, accurate diagnostics contribute in a big way
towards the management of disease. This includes the entire treatment process which
consists of disease detection, prognosis, diagnosis, treatment planning and post-treatment
monitoring. To this end, we are continuing to invest in creating an efficient
technology-backed network that can align with the growth in sample volumes.
Reflecting on the year gone by, I am delighted to share that we have achieved 15.5%
growth in the non-COVID revenue in FY 2022-23. We have proudly served about 26.9 million
patients in FY 2022-23. This has come on the back of a sharp focus on core operations
across the country including Tier-2 and Tier-3 cities and investments in digital
infrastructure. It is worthwhile to note that, since the fiscal marked the first year
following two consecutive years dominated by the pandemic, our march towards reaching
normalcy was the fastest in the industry. Owing to this, during the fiscal, we were
successful in redeployment of the investments we had made for Covid. We continued to make
progress across our three strategic pillars that include geographical expansion, creating
a unique fresh-size portfolio and augmenting the technology infrastructure for the future.
A key highlight has been the unveiling of our Mumbai Reference Lab at Vidyavihar. This
has immediately resulted in the increased testing of the high end tests and it is also the
first private lab in West India to have a BSL Level-III biocontainment lab for
microbiology and virology testing. This speaks leaps and bounds of our commitment to offer
best-in-class services to our patients by bringing them a unique testing experience at
affordable rates. We are proud to announce the acquisition of a second electron microscope
at our National Reference Lab in Rohini in Delhi while none of the private players in the
country have even one electron microscope. Additionally, towards our efforts in
strengthening our technological capabilities, we began implementing and upgrading our lab
information system and advanced tools like artificial intelligence and data mining. We are
again the first in the country to have AI based Histopathological Diagnosis in the field
of Prostate and Breast biopsies. We remain the number one Histopathology and Renal biopsy
testing center in the world. Needless to add, this enabled us to achieve enhanced
operational efficiencies and quicker turnaround time or TAT. In today's ever-evolving
business landscape, the significance of Environmental, Social, and Governance (ESG)
principles cannot be understated. As a responsible company, we recognise the importance of
incorporating ESG practices into our operations. Over the years, we have taken significant
strides to not only thrive within our industry but also assume full responsibility for our
immediate environment.
We also take pride in being a people-oriented organisation. We are happy to share with
you that the international Newsweek magazine has given us the 15th ranking worldwide in
the hundred Global Most Loved Work Places 2023'. In this list, there are only two
other Indian companies which are ranked much lower. We firmly believe in creating an
inclusive and diverse workforce. To that end, we have actively recruited differently-abled
individuals and provided them with employment opportunities within our organisation. We
have also invested in building facilities that cater to the needs of differently-abled
employees.
As we go forward, we are very optimistic about the future of the industry. We believe
that diagnostics will play an important role in the healthcare industry, as it serves as
the crucial first step in the healthcare journey remember Test, Track and
Treat'! Moreover, a significant portion of India remains underserved in terms of both
diagnostics and healthcare access. As the government takes steps to establish healthcare
networks in these underserved regions, we anticipate a positive ripple effect on disease
awareness, discovery, and treatment. Given that diagnostics form the cornerstone of
healthcare decision-making, our industry is poised to benefit from this increased
awareness and access. As the leader in this space, we believe all of this will accrue to
us in some form and shape in the long term. We are focusing on certain areas that will
amplify our growth in the coming years. These include: E xploring possible synergies
The diagnostic industry is experiencing competition from various directions with
multiple players exploring diversification opportunities. In response to this dynamic
environment, we are also looking forward for possible synergies to drive our growth and
maintain a competitive edge Pushin g higher test portfolio We recognise the importance of
offering a diverse and comprehensive test portfolio to meet the evolving needs of
healthcare providers and patients. We are continuing to add new tests to our test menu and
diversify our reach to higher franchise share of patient service centers P enetrate in
Tier-2 and Tier-3 markets - We see an immense potential in Tier-2 and Tier-3 markets,
where access to diagnostic services may be limited. We are therefore looking forward to
extend our reach in these markets, bringing our expertise, technology, and services closer
to the underserved population E xploring opportunities in
Southern Market - Witnessing the southern region as a significant growth potential for
our organisation, we are also actively exploring opportunities to expand our presence in
this market Most importantly, people are at the heart of our organisation and we remain
committed to being people and customer oriented, placing their needs at the forefront of
our operations. We also remain dedicated to giving back to the communities we serve and
making a positive impact on society.
In conclusion, we appreciate your continued support and trust as we propel our
organisation towards sustained success in the competitive landscape.
Thank you for your confidence in our Company.
Warm regards,
(Hony) Brig. Dr. Arvind Lal, - Padma Shri
Executive Chairman
  Â
Dr Lal Pathlabs Ltd
Company History
Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service centers and 10,938 pickup points as of 31 March 2023. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. Apart from these, the catalogue of services includes 481 test panels, 2763 pathology tests and 1947 radiology and cardiology tests.
Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s. Central Clinical Laboratory and M/s. Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt. Ltd.'
Dr. Lal PathLabs Limited was incorporated as a a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi. The business of the Partnership Firm, Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company converted into a Public Limited pursuant to a Special Resolution of the Shareholders of the Company at an EGM held on August 7, 2015. Consequently, name of the Company was changed to Dr. Lal PathLabs Limited' and a fresh Certificate of Incorporation pursuant to the change of name was granted by the RoC on August 19, 2015.
The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited.
The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the Company with the Company with effect from 1 April 2017. The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Hon'ble National Company Law Tribunal (NCLT), on October 23, 2018 and December 11, 2018 respectively. Pursuant thereto, in accordance with the terms of the scheme, Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1, 2017 (being the appointed date) and consequently stands dissolved without winding up.
The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh.
On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.
Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international arena.
During the FY2019, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12, 2018, respectively, as wholly owned subsidiaries of the Company. As on 31 March 2019,the company has 5 domestic and 3 overseas subsidiaries under its roof.
The Board of Directors of your Company in their meeting held on February 3, 2020, approved a Scheme of Amalgamation ('the Scheme') between the Company and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company. The Company is in the process of filing a petition Application before the National Company Law Tribunal, New Delhi for approval of the Scheme of Amalgamation.
During the FY2020, Company's Wholly Owned Subsidiary viz M/s. PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s. APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company. Also Dr. Lal PathLabs Kenya Private Limited was incorporated on August 6, 2019, as a Wholly Owned Subsidiary of the Company in Kenya. The Company has subscribed to equity share capital amounting to KES 10 million (Rs 7.10 million) consisting of 9,880 shares of KES 100.
As on 31 March 2020,the company has 7 domestic and 4 overseas subsidiaries under its roof.
During the year 2019-20, the Company has made a further investment of Rs 599.00 million and Rs 9.00 million in this subsidiary Company Pathlabs Unifiers Private Limited and Dr. Lal Ventures Private Limited respectively through subscription of additional shares.
During the quarter ended 30 June 2020,the company has made a further investment of Rs 15 million in its whollyowned subsidiary Pathlabs Unifiers Private Ltd,through subscription of additional equity shares.
Subsequent to the quarter ended 30 September 2020,pursuant to approval of the Board of Directors of Pathlabs Unifiers Private Ltd(PUPL),a whollyowned subsidiary,PUPL has signed binding term sheets on 06 November 2020,for the acquisition of the business of Bindish Diagnostic Laboratory LLP,Gujarat,on a going concern basis,for a purchase consideration not exceeding Rs 40 million and equity stake of 40% in ChanRe Diagnostic Services Private Ltd,Bengaluru,for a purchase consideration not exceeding Rs 175 million. Both of these companies are engaged in providing pathological diagnostic services.
During the quarter ended 31 December 2020, the company has made a further investment of Rs 225 million in its whollyowned subsidiary,Pathlabs Unifiers Private Ltd,through subscription of additional equity shares. Also the company made a further investment of Rs 40 million in its whollyowned overseas subsidiary,Dr.Lal Pathlabs Kenya Private Ltd,through subscription of additional equity shares.
During year 2020-21, the Company added 15 labs, 600 collection center and 2200 pick-up points. It had overall 231 clinical labs, 3,705 patient service centres and 9,247 pickup-up points as on March 31, 2021.
The Board of Directors of the Company in their meeting on February 3, 2020, approved a Scheme of Amalgamation between Dr. Lal PathLabs Limited (the Transferee Company) and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company (Transferor Company), which was sanctioned on May 13, 2022 and the appointed date for the Scheme is April 1, 2020.
During the year 2021-22, the Company acquired 100% stake in M/s Suburban Diagnostics (India) Private Limited and consequently, Suburban became a Wholly Owned Subsidiary of the Company, effective November 12, 2021. It introduced 46 labs, 1,026 patient service centers and 1,352 pick-up points.
The Company opened its Reference Lab at Vidyavihar, in Mumbai in Jan' 23. Dr. Lal PathLabs expanded its National Reference Lab in Rohini, Delhi, by acquiring a second electron microscope, an upgraded lab information system and advanced tools such as artificial intelligence and data mining.
During FY 2023, the Company operated a network of 277 clinical labs, including the prestigious National Reference Lab in Delhi and the Regional Reference Lab in Kolkata, Bangalore and Mumbai. Additionally, with 5,102 Patient Service Centres (PSCs) and 10,938 Pick-up Points (PUPs), the Company has established a nationwide presence. APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of Company (APL/ Transferor Company), was amalgamated with Dr. Lal PathLabs Limited (the Company/ Transferee Company) effective on March 27, 2023. The Company launched 134 tests in FY' 23 to expand the Super Specialty Portfolio.
Dr Lal Pathlabs Ltd
Directors Reports
Dr Lal Pathlabs Ltd
Company Background
Incorporation Year | 1995 |
Registered Office | E-2 Block Sector 18,Rohini New Delhi,New Delhi-110085 |
Telephone | 91-011-3024 4149,Managing Director |
Fax | 91-011-2788 2134 |
Arvind LalOm Prakash Manchanda Company Secretary | |
Auditor | Deloitte Haskins & Sells LLP |
Face Value | 10 |
Market Lot | 1 |
Listing | BSE,NSE, |
Registrar | Link Intime India Pvt Ltd Noble Heights 1st Fl,Plot NH 2 C-1 Block ,LSC Janakpuri ,New Delhi - 110058 |
Dr Lal Pathlabs Ltd
Company Management
Director Name | Director Designation | Year |
---|
Arvind Lal | Chairman / Executive Director | 2023 |
Vandana Lal | Executive Director | 2023 |
Archana Lal Erdmann | Non Executive Director | 2023 |
Om Prakash Manchanda | Executive Director & MD | 2023 |
Rahul Sharma | Non Executive Director | 2023 |
Anoop Mahendra Singh | Independent Non Exe. Director | 2023 |
Harneet Singh Chandhoke | Independent Non Exe. Director | 2023 |
Sunil Varma | Lead Independent Non Executive | 2023 |
Saurabh Srivastava | Independent Non Exe. Director | 2023 |
Somya Satsangi | Independent Non Exe. Director | 2023 |
Rohit Bhasin | Independent Non Exe. Director | 2023 |
Arun Duggal | Independent Non Exe. Director | 2023 |
Gurinder Singh Kalra | Independent Non Exe. Director | 2023 |
RAJIT MEHTA | Independent Non Exe. Director | 2023 |
Dr Lal Pathlabs Ltd
Listing Information
Listing Information |
---|
BSE_500 |
BSE_HC |
CNX500 |
BSESMALLCA |
CNXMIDCAP |
CNX200 |
BSEALLCAP |
BSESMALLSE |
MID150 |
LMI250 |
MSL400 |
NFTYLM250 |
NFTYMC150 |
NFTYMSC400 |
NFTM150Q50 |
NFTYHEALTH |
NF500M5025 |
NFTYTOTMKT |
NFTYMIDSMH |
Dr Lal Pathlabs Ltd
Finished Product
Product Name | Unit | Installed Capacity | Production Quantity | Sales Quantity | Sales Value |
---|
Sale of Services | NA | 0 | 0 | 0 | 1768.791 |
Other Operating Revenue | NA | 0 | 0 | 0 | 0.239 |
Sales | NA | 0 | 0 | 0 | 0 |
Scrap Sales | NA | 0 | 0 | 0 | 0 |